The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor ...

Pediatric doses associated with consistent exposure across age are still unknown. Therefore, we aim to identify a dosing strategy for ivermectin treatment in both pre-school-aged children (2–5 years ...

Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg ...

Quercetin has most often been used by adults in doses of 250-1000 mg by mouth daily for up to 12 weeks. Speak with a healthcare provider to find out what dose might be best for a specific condition.

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

"Stelara has long been a cornerstone treatment for chronic inflammatory conditions, but with an annual cost up to $125,000 per patient, it's a financial burden on members and payers alike," said ...

They were one of the biggest boy bands of the late '90s and early noughties, with three Number 1 singles and a chart-topping album to their name, and now Five appear to be teasing some big news.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. It is hard for a weighed-down aeroplane to achieve lift-off. Last week, a US bankruptcy judge formally ...

The vibes are shifting on Wall Street. Popular gauges of investor sentiment are showing that the pervasive sense of optimism that followed President Donald Trump’s election victory in November ...

Biocon Biologics has announced that Yesintek (ustekinumab-kfce) is now available to patients in the United States, and is one of the first Stelara (ustekinumab ... covering the same indications and ...

John­son & John­son is su­ing Sam­sung Bioepis for al­leged­ly breach­ing the terms of a con­tract re­gard­ing the launch of the Ko­re­an biotech’s Ste­lara biosim­i­lar. … ...